REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - The Rosen Law Firm is reminding investors who purchased Regeneron Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 10, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Allegations Against Regeneron - The lawsuit alleges that Regeneron made false and misleading statements regarding its pricing practices for Eylea, including undisclosed payments to distributors that affected the selling price [5]. - Specific claims include that Regeneron’s actions misled investors about the true sales figures and violated the False Claims Act by overstating the Average Sales Price reported to federal agencies [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading nature of Regeneron's statements about its business and operations [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes its experience and success in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].